COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler; Elisabeth G.E. de Vries; Corine H. GeurtsvanKessel; John B. Haanen; Bernhard Wörmann; Samra Turajlic; Marie von Lilienfeld-Toal

doi:10.1038/s41571-022-00610-8

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler
, Elisabeth G.E. de Vries
, Corine H. GeurtsvanKessel
, John B. Haanen
, Bernhard Wörmann
, Samra Turajlic
, Marie von Lilienfeld-Toal^*

^*Corresponding author for this work

Virology

The Francis Crick Institute
University Medical Centre Groningen
Netherlands Cancer Institute
Charité – Universitätsmedizin Berlin
The Institute of Cancer Research and Royal Marsden NHS Foundation Trust
Jena University Hospital
Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute

Research output: Contribution to journal › Review article › Academic › peer-review

180 Citations (Scopus)

Abstract

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

Original language	English
Pages (from-to)	385-401
Number of pages	17
Journal	Nature Reviews Clinical Oncology
Volume	19
Issue number	6
Early online date	11 Mar 2022
DOIs	https://doi.org/10.1038/s41571-022-00610-8
Publication status	Published - Jun 2022

Bibliographical note

Acknowledgements:
The authors thank S. Oosting of the University of Groningen for support in data research. The work of E.G.E.de V. and J.B.H. is supported within the VOICE study by project grant 10430072010005 ZonMw, The Netherlands Organisation for Health Research and Development. The work of M.v.L.-T. is supported by the German Research Foundation within the Collaborative Research Centre/Transregio 124 FungiNet, DFG project no. 210879364 (project A1) as well as the Deutsche Krebshilfe OncoReVir Registry (no. 70113851). The work of A.F. is supported by funding from the European Union’s Horizon 2020 Research and Innovation program under Marie Skłodowska-Curie grant no. 892360. The work of S.T. is supported by Cancer Research UK (grant no. C50947/A18176). This work was also supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CRUK) (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030), the UK Medical Research Council (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030) and the Wellcome Trust (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030).

Publisher Copyright: © 2022, Springer Nature Limited.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41571-022-00610-8

https://www.nature.com/articles/s41571-022-00610-8.pdf

Cite this

@article{3e84f54bf77b4c03aea17b3ed8cd62aa,

title = "COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety",

abstract = "Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.",

author = "Annika Fendler and \{de Vries\}, \{Elisabeth G.E.\} and GeurtsvanKessel, \{Corine H.\} and Haanen, \{John B.\} and Bernhard W{\"o}rmann and Samra Turajlic and \{von Lilienfeld-Toal\}, Marie",

note = "Acknowledgements: The authors thank S. Oosting of the University of Groningen for support in data research. The work of E.G.E.de V. and J.B.H. is supported within the VOICE study by project grant 10430072010005 ZonMw, The Netherlands Organisation for Health Research and Development. The work of M.v.L.-T. is supported by the German Research Foundation within the Collaborative Research Centre/Transregio 124 FungiNet, DFG project no. 210879364 (project A1) as well as the Deutsche Krebshilfe OncoReVir Registry (no. 70113851). The work of A.F. is supported by funding from the European Union{\textquoteright}s Horizon 2020 Research and Innovation program under Marie Sk{\l}odowska-Curie grant no. 892360. The work of S.T. is supported by Cancer Research UK (grant no. C50947/A18176). This work was also supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CRUK) (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030), the UK Medical Research Council (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030) and the Wellcome Trust (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030). Publisher Copyright: {\textcopyright} 2022, Springer Nature Limited.",

year = "2022",

month = jun,

doi = "10.1038/s41571-022-00610-8",

language = "English",

volume = "19",

pages = "385--401",

number = "6",

}

TY - JOUR

T1 - COVID-19 vaccines in patients with cancer

T2 - immunogenicity, efficacy and safety

AU - Fendler, Annika

AU - de Vries, Elisabeth G.E.

AU - GeurtsvanKessel, Corine H.

AU - Haanen, John B.

AU - Wörmann, Bernhard

AU - Turajlic, Samra

AU - von Lilienfeld-Toal, Marie

N1 - Acknowledgements: The authors thank S. Oosting of the University of Groningen for support in data research. The work of E.G.E.de V. and J.B.H. is supported within the VOICE study by project grant 10430072010005 ZonMw, The Netherlands Organisation for Health Research and Development. The work of M.v.L.-T. is supported by the German Research Foundation within the Collaborative Research Centre/Transregio 124 FungiNet, DFG project no. 210879364 (project A1) as well as the Deutsche Krebshilfe OncoReVir Registry (no. 70113851). The work of A.F. is supported by funding from the European Union’s Horizon 2020 Research and Innovation program under Marie Skłodowska-Curie grant no. 892360. The work of S.T. is supported by Cancer Research UK (grant no. C50947/A18176). This work was also supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CRUK) (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030), the UK Medical Research Council (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030) and the Wellcome Trust (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169 and FC001030). Publisher Copyright: © 2022, Springer Nature Limited.

PY - 2022/6

Y1 - 2022/6

N2 - Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

AB - Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

UR - https://www.scopus.com/pages/publications/85126096439

U2 - 10.1038/s41571-022-00610-8

DO - 10.1038/s41571-022-00610-8

M3 - Review article

C2 - 35277694

AN - SCOPUS:85126096439

SN - 1759-4774

VL - 19

SP - 385

EP - 401

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 6

ER -

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this